DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Implanon (Etonogestrel Subcutaneous) - Published Studies

 


Nutrilib.com
A comprihensive source of nutritional information

Implanon Related Published Studies

Well-designed clinical trials related to Implanon (Etonogestrel Subcutaneous)

7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. [2007.09]

Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. [2006.01]

A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. [2006.01]

A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. [2006.01]

Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis. [2005.12]

A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. [2005.04]

Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests -- a randomized comparative study with Norplant implants. [2004.11]

Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids--a randomized comparative study. [2003.09]

[A randomized study comparing the efficacy and bleeding pattern of Implanon and Norplant hormonal contraceptive implant] [2003.07]

Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. [2002.08]

Implanon contraceptive implants: effects on carbohydrate metabolism. [2001.03]

Effect of Implanon use on selected parameters of thyroid and adrenal function. [2000.11]

Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. [2000.09]

The effects of Implanon on lipid metabolism in comparison with Norplant. [1999.11]

Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette and Liseta. [1999.10]

A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. [1999.07]

Twenty-four month comparison of apolipoproteins A-1, A-II and B in contraceptive implant users (Norplant and Implanon) in Birmingham, United Kingdom. [1998.10]

Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial. [1998.08]

Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. [1998.04]

Well-designed clinical trials possibly related to Implanon (Etonogestrel Subcutaneous)

Male hormonal contraception: a double-blind, placebo-controlled study. [2008.07]

Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. [2006.09]

Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. [2006.09]

A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. [2006.02]

Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. [2005.11]

Extended regimens of the contraceptive vaginal ring: a randomized trial. [2005.09]

The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. [2005.07]

Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners. [2005.04]

Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. [2005]

The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. [2004.03]

The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. [2004.02]

The combined contraceptive ring NuvaRing and spermicide co-medication. [2003.04]

Complete and robust ovulation inhibition with NuvaRing. [2002.12]

Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. [2001.05]

The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual blood loss: a double-blind, dose-finding, placebo-controlled study. [2000.03]

Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. [1999.01]

A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK. [1998.11]

Prodrug versus drug effects of 150 micrograms desogestrel or 3-keto-desogestrel in combination with 30 micrograms ethinylestradiol on hormonal parameters: relevance of the peak serum level of 3-keto-desogestrel. [1995]

Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene. [1994.10]

Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives. [1993.12]

Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive. [1992.09]

Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. [1990.10]

The in vivo release characteristics of a multi-compartment vaginal ring releasing 3-keto-desogestrel. [1989.11]

Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel. [1989.06]

Other research related to Implanon (Etonogestrel Subcutaneous)

Tolerability and clinical safety of Implanon. [2008.06]

The effects of Implanon on menstrual bleeding patterns. [2008.06]

The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. [2008.06]

Implanon: a new contraceptive implant. [2008.05]

Contraceptive efficacy and side effects of Implanon. [2007.12]

Side effects and acceptability of Implanon: a pilot study conducted in eastern Turkey. [2007.09]

The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring. [2007.08]

Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. [2007.08]

Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis. [2007.06]

The effects of implanon in the symptomatic treatment of endometriosis. [2005.10]

Other possibly related research studies

The decline of laparoscopic sterilisation. [2008.02]

Progress and prospects in male hormonal contraception. [2008.06]

The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. [2008.06]

The contraceptive implant. [2007.12]

Contraceptive vaginal ring. [2007.12]

Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. [2007.10.17]

Long-acting contraceptives in adolescents. [2007.10]

Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. [2007.07.18]

Alternatives to oral regimens of contraception. [2007.06]

Compound versus fundamental imaging in the detection of subdermal contraceptive implants. [2007.03]

Bleeding patterns of women using extended regimens of the contraceptive vaginal ring. [2007.03]

A diurnal variation in testicular hormone production is maintained following gonadotrophin suppression in normal men. [2007.01]

Etanercept treatment of erythema nodosum. [2007.07]

One-year assessment of women receiving sub-dermal contraceptive implant at Siriraj Family Planning Clinic. [2008.06]

Contraceptive devices: intravaginal and intrauterine delivery systems. [2008.09]

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008